Literature DB >> 3495503

The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies.

C F Scott, J M Lambert, V S Goldmacher, W A Blatter, R Sobel, S F Schlossman, B Benacerraf.   

Abstract

We studied in mice the in vivo pharmacokinetics and toxicity of murine monoclonal antibodies (MCA) and of disulfide-linked MCA conjugates of gelonin, a ribosomal inhibitor prepared from the seeds of Gelonium multiflorum. Iodinated MCA with specificity for human determinants and of gamma 1 or gamma 2a isotype had a circulatory half life (T 1/2) in the mouse of 4 days, which is consistent with previously published estimates of the circulatory T 1/2 of heterogeneous murine IgG. Iodinated murine MCA with specificity for murine determinants had a much shorter T 1/2, probably reflecting antigen binding. This effect could be partially overcome by the simultaneous injection of unlabeled MCA of identical specificity. Clearance of MCA-gelonin conjugates was characterized by an initial rapid phase lasting 8-12 h with a T 1/2 or from 4 to 7 h, followed by a slower clearance phase with T 1/2 approaching that of MCA. Moreover, the presence of significant amounts of intact conjugate in the murine circulation was demonstrable, by SDS gel electrophoresis, for up to 48 h post injection. Intraperitoneal injection of MCA-gelonin conjugate resulted in circulating levels identical to those achieved after i.v. administration after an initial 4 h equilibration. The LD50 of MCA-gelonin conjugates was approximately 25 mg/kg (i.v.) while that of gelonin was approximately 75 mg/kg (i.v.) MCA alone showed no toxicity in doses in excess of 150 mg/kg. At doses below the LD50 immunoconjugates caused a dose-dependent reversible weight loss. The main site of toxicity of MCA-gelonin conjugates was the liver; histopathological examination revealed dose-dependent foci of necrosis and acute inflammation. No pathology was observed in lung, spleen, kidney, gut or brain. The relationship to previous work in this area is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495503     DOI: 10.1016/0192-0561(87)90096-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  11 in total

1.  Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

Authors:  C F Scott; W A Blättler; J M Lambert; R S Kalish; C Morimoto; S F Schlossman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Authors:  Christopher M Pirie; Benjamin J Hackel; Michael G Rosenblum; K Dane Wittrup
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

3.  Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.

Authors:  L Cattel; L Delprino; P Brusa; F Dosio; P M Comoglio; M Prat
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.

Authors:  C F Scott; V S Goldmacher; J M Lambert; R V Chari; S Bolender; M N Gauthier; W A Blättler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 5.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

6.  Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.

Authors:  D J Flavell; S Cooper; B Morland; S U Flavell
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

7.  Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.

Authors:  Joseph Ryan Polli; Ping Chen; Brandon M Bordeau; Joseph P Balthasar
Journal:  AAPS J       Date:  2022-03-25       Impact factor: 3.603

8.  Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.

Authors:  F Stirpe; E J Wawrzynczak; A N Brown; R E Knyba; G J Watson; L Barbieri; P E Thorpe
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

9.  Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles.

Authors:  Xingfang Su; Nicole Yang; K Dane Wittrup; Darrell J Irvine
Journal:  Biomacromolecules       Date:  2013-03-11       Impact factor: 6.988

10.  Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.

Authors:  D K Adigbli; D G G Wilson; N Farooqui; E Sousi; P Risley; I Taylor; A J Macrobert; M Loizidou
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.